Global Colloids Blood Plasma Market 2026 – 2035

The global colloids blood plasma market size is expected to be 3.5 billion USD in 2025. It is also expected to grow to 3.68 billion USD in 2026 and to about 5.91 billion USD in 2035, with an annual CAGR of 5.3% between 2026 and 2035. The market is growing because more people want it and more people are getting trauma cases, surgeries, and critical care admissions. Plasma-derived therapy is used to treat autoimmune diseases, hemophilia, and disorders that make the immune system weak.

The market is also growing because of improvements in plasma fractionation technologies, the growth of healthcare infrastructure in developing countries, and the growing acceptance of colloids solutions for volume resuscitation.

Market Highlight

• North America was leading the colloids blood plasma market with 45% market share in 2025.

• Asia Pacific to grow at a CAGR of 5.6% between 2026 and 2035, driven by surging chronic disease.

• Albumin-based colloids segment is to account for 45% market share by product type in 2025, leading global adoption.

• By product type, gelatin-based colloids will experience the highest CAGR of 5.5% between 2026 and 2035.

• Application-wise, shock held the largest share of 41.5% in 2025, while diagnostic centers are projected to have the highest CAGR of 5.6% during 2026-2035.

• Hospital segment to capture 55% market share by end use in 2025.

• In 2025, the overall colloids blood plasma market is dominated by ambulatory surgical centers (ASCs).

Significant Growth Factors

The Colloids blood plasma market has a lot of potential to grow because of factors.

• Rising Prevalence of Neurological and Musculoskeletal Disorders: A lot of people are getting disorders like epilepsy Parkinson’s disease, Alzheimer's, and stroke. Also, musculoskeletal disorders like neuropathies and myopathies are becoming more common. The World Health Organization says that neurological disorders cause a lot of disability and death worldwide. As people get older, the number of cases is going up. This is why doctors need tools like colloidsal blood plasma to diagnose and treat these diseases.

• New Technologies and Digital Health: Colloidal blood plasma is getting better because of technologies like artificial intelligence and wearable devices. These new tools help doctors make accurate diagnoses and reduce their workload. Some studies say that these tools can improve diagnosis by up to 15%. We also have devices that can monitor patients outside of hospitals. This makes it easier for doctors to take care of patients and provide tele-neurology services. We can also store data in the cloud, which makes it easier to access and analyze.

• More Tele-neurology and Remote Monitoring: A lot of people need care but they cannot always get to a hospital. This is why tele-neurology and remote monitoring are becoming more popular. Remote monitoring allows patients to get diagnosed without having to travel distances. This reduces hospital visits saves money and helps patients follow their treatment plans. Telehealth is also reducing hospital visits and making care faster.

• Government Support and Investment in Healthcare: Governments are supporting healthcare by providing funding and favorable policies. They are also investing in health programs. This support is helping to increase the use of colloidsal blood plasma. Additionally governments and private companies are working together to improve healthcare infrastructure, including hospitals and telemedicine networks. This is making it easier for people to get care especially in countries that are still developing their healthcare systems. The colloids blood plasma market is growing because of these factors. It will continue to grow as healthcare systems improve.

What are the Major Advances Changing the Colloids blood plasma Market Today

• The number of people getting hurt having surgeries and needing care is going up: This means we need solutions to help their bodies. There are accidents, burns and surgeries happening around the world. For example trauma is a leading cause of death among young people. In the US there are over 32,000 burn injury cases each year. In the UK there are over 27,000 artery bypass procedures done every year. All these situations need treatments to help patients recover. Plasma expanders are widely used to help patients in these situations, which is increasing their demand.

• There is a growing need for therapies made from plasma: These therapies, such as albumin and immunoglobulins are used to treat conditions like immunodeficiency disorders, hemophilia, liver diseases and autoimmune conditions. As more people get these conditions the demand for plasma-derived therapies increases. New technologies have made it possible to produce these therapies efficiently making them more accessible. This has led to an increase in their use.

• Hospitals, emergency care units and surgical centers are being built in places: This expansion of healthcare infrastructure is helping more people get the care they need. As a result plasma volume expanders are being used often. There are also ICU beds and emergency response systems available. This is driving up the demand for colloids solutions in emergency situations. For instance around 70 million liters of plasma are collected every year. This shows how much healthcare infrastructure is supporting plasma therapies.

• New technologies are making plasma products safer and more effective: For example advancements in plasma processing and pathogen reduction technologies have reduced the risk of reactions. Regulations are also pushing manufacturers to improve their production processes. This is leading to the development of more effective colloids blood plasma products.

• The world's population is getting older: This is driving up the demand for plasma-based therapies. Older people are more likely to get diseases need surgeries and get critical illnesses. Conditions like diseases, kidney disorders and liver dysfunction often require plasma-based therapies. As there are older people, the demand for these therapies will keep increasing.

• Governments and healthcare organizations are supporting blood plasma collection and distribution: They are funding initiatives to improve plasma donation rates and plasma fractionation facilities. This is helping to increase the supply of plasma-derived therapies. In markets reimbursement frameworks are also encouraging the use of these therapies. In emerging economies private investments are increasing, which is expected to drive market growth.

Category Wise Insights

By Product Type

What makes Albumin-Based Colloids dominate the market?

Albumin-based colloids have an edge over their synthetic counterparts in the blood plasma market as they are natural, functional and clinically accepted and used for blood volume restoration and other therapies. The bulk of uses of plasma protein are for albumin with over 60% of plasma-derived therapies worldwide linked to albumin and immunoglobulin. One of the most popular colloids, it is frequently used in liver diseases, burns, shock and low albumin states. Doctors may prefer albumin over synthetic colloids as it is a safer and less nephrotoxic option. Additionally, the use of albumin-based products is increasing among hospitals and ICUs, while fractionation capacity keeps on expanding.

Some experts have claimed that a cheaper and safer alternative to HES solutions is gelatin based colloids. They are generally used for short-term plasma volume expansion during surgery and emergency situations, particularly when cost is a consideration. The use of HES has declined due to safety concerns, including an increase in the risk of kidney injury and death in severely ill patients. As a result, hospitals are now considering gelatin as a substitute. Fluid resuscitation is extremely important in critical care and in the perioperative setting. Millions of people require this treatment type each year. Since gelatin acts quickly and has a short half-life in the blood, it is ideal for controlled fluid replacement. It’s rapidly growing in developing countries and mid-level healthcare centers with increasing usage.

By Application

Why is Shock provider dominating the market?

The leading application segment is shock, driven by the increasing use of colloids for rapid plasma volume expansion and hemodynamic stabilization in life-threatening conditions such as septic and hypovolemic shock. Sepsis is responsible for shock more often than any other disease. Approximately 49 million individuals suffer from sepsis worldwide each year. According to the WHO, sepsis is responsible for close to 20% of all deaths globally. Shock management is not possible without the immediate use of fluids. Any fluid may be used, but colloids, especially albumin, are largely used these days. This is done to replenish the circulating volume in tissues and maintain blood pressure. According to clinical studies, a large part of patients in the ICU required plasma or colloids during shock treatment; thus, they are essential in the emergency. The rising occurrence of critical illnesses, traumatic cases, and ICU admissions across the globe is causing continuous demand in this segment. This vital and lifesaving function assures that shock will always remain in the application.

The surgery segment is projected to record the highest growth rate due to the rapid increase in global surgical volumes and the necessity for intraoperative fluid management. Each year, the world’s largest health estimates indicate annual growth in surgical procedures, with over 300 million surgical procedures. This growth has led to an increasing demand and consumption for the plasma volume expander. Colloids are more utilized during surgical days in hemodynamic stabilization, in preventing hypovolemic crisis, and in preventing fluid overload as compared to crystalloids. Recently, advances in the surgical technique, especially minimally invasive and other high-risk procedures, require precise fluid management. The rise in the number of procedures is also credited to expanding healthcare infrastructure and better availability of surgical care in developing economies. Clinical guidelines highlight that balanced fluid therapy in the perioperative period better supports the use of colloids. Surgery is becoming increasingly popular among patients.

By End Use

Why Hospitals dominate the Market?

Hospitals represent a dominant segment of the colloids blood plasma market as they are considered the main sites of critical care and complex surgeries/emergency interventions. Most patients requiring colloids therapy, such as septic, trauma and shock patients, as well as chronic disease patients are treated in hospitals. Research reports have concluded that 22% of patients treated in ICUs develop sepsis, and a high volume of patients receive plasma-based therapies, requiring large fluid resuscitations, reflecting the high consumption rates in hospitals. Moreover, hospitals maintain the required systems for continuous administration and management of colloids solution such as intensive care units, blood banks and sophisticated monitoring systems. They provide extensive capability to meet the needs of critical cases requiring prompt medical intervention and handling large volume of patient streams. In hospitals, advanced multidisciplinary team support and infrastructure are well integrated with various specialties making hospitals the largest end-use segment of the market.

Ambulatory surgical centers (ASCs) comprise the fastest-growing segment within the colloids blood plasma market as they are associated with the worldwide tendency towards outpatient procedures and less invasive surgeries. ASCs can provide the benefits of same-day surgery, leading to reduced lengths of hospital stay and decreased healthcare expenses. Despite being treated in outpatient settings, patients undergo different surgical procedures that necessitate proper perioperative fluid management, where colloids play a crucial role. The results from clinical studies demonstrate the importance of fluid therapy as a basic component of surgical treatment in any setting. Technical innovations in anesthesia and surgical methodologies have expanded the range of operations performed at ASCs in a safe and efficient manner. Moreover, the overall focus on enhancing cost effectiveness, reducing the hospital workload, and increasing patient convenience will accelerate the rate of growth in the ASCs market segment. The decentralization of medical care will boost the utilization of colloids.

Report Scope

Regional Analysis

How Large is the Asia Pacific Market?

Why was Asia Pacific Dominating the Market in 2025?

The Asia Pacific colloids blood plasma market is projected to dominate in 2025 on the back of its large population, the rising burden of diseases, and rapid growth in the healthcare infrastructure. The region constitutes about 60% of the total population worldwide which drives a huge demand for critical care treatments. According to the United Nations, the population of people aged 60 years or more will be higher than 600 million by 2030 in the Asia Pacific which further leads to an increase in the cases of chronic diseases, surgeries and ICU admissions. The World Health Organization states that the burden of injuries from road traffic accidents and trauma is particularly high in low- and middle-income countries, where most of the Asia Pacific nations lie. Increase in investments, expansion of the hospitals and improvement in the access to emergency services all contribute towards demand for plasma-derived products like albumin in the Asia Pacific and make it the leading regional market.

China Market Trends

The market in China constitutes one of the major markets for colloidsal blood plasma due to a huge population and age demographics, combined with an increase in capacity of hospitals for critical care. The country accounts for more than 1.4 billion citizens, out of whom about 280 million people are aged 60 years and above (Source: National Bureau of Statistics of China), who mostly require critical care therapies. The rising burden of chronic diseases, such as cardiovascular disease and liver disease, further enhances the need for albumin and other plasma products. Hospitals' and ICUs' capacities have grown exponentially in the country, thus making access to superior critical care more accessible. The government is aggressively promoting plasma collection and in-country fractionation. Increased healthcare expenditures, coupled with a broad reach of health insurance, is supporting the demand for plasma-derived therapeutics and sustaining market growth in both urban and rural areas.

Why is North America Enjoying Consistent Growth?

The North American colloids blood plasma market is experiencing consistent growth, owing to the strong healthcare infrastructure, increased ICU capacities, and robust plasma collection networks in the U.S. It is worth mentioning that the U.S. is considered to have the largest market share globally for plasma collection; it is responsible for nearly 60-65% of all plasma collections globally (Source: Industry reports & public health bodies). The region is characterized by a high prevalence of chronic diseases; for instance, the CDC estimates that around 6 in 10 adults in the U.S. Suffer from at least one chronic condition, which necessitates surgical intervention or critical care treatment. Moreover, the region has several well-established plasma fractionation plants, along with the stringent regulatory frameworks that ensure a consistent supply of superior quality products. Increased expenditure on healthcare, as well as wider application of plasma products (including albumin for shock & liver disease) in the treatment of patients, drives sustained demand.

How Large is the U.S. Market?

The U.S. Colloids blood plasma market size is estimated to be USD 1.37 Billion in 2025 and is expected to increase at a faster rate of 5.03% from 2026 to 2035.  

U.S. Market Trends

The market in the U.S. Is well known for high adoption of plasma-derived therapies, especially the high clinical reliance on albumin in critical care settings. The market for colloidsal blood plasma products, including albumin, is substantially boosted by its widespread use in managing conditions like sepsis, with over 1.7 million adult cases recorded each year in the U.S. (Source: Health Department). Many of these cases are admitted to ICUs and require rapid intravenous fluid and colloids administration. The U.S. Is also the global leader in plasma collection and fractionation, which contributes significantly to an abundant and stable supply of plasma-derived products. Adoption of holistic, evidence-based, and advanced critical care practices has greatly improved treatment outcomes of patients. Enhanced collaborations among medical institutions and the biopharmaceutical industry are spurring innovation and increased usage of colloidsal blood plasma.

Why is Europe Dwelling on Efficiency and Clinical Standardization?

The European market is regarded as a major market owing to its well-structured healthcare systems, universal healthcare access and the strict guidelines for treatment procedures. As per Eurostat, nearly more than 20% of the European population is 65 years or older. This is resulting in the increased demand for surgical procedures, treatment for chronic conditions and other critical care services. The healthcare systems in Europe place a lot of emphasis on evidence based medicines which is further leading to controlled & standardize usage of colloids (specifically albumin). The European region has laid stringent regulatory frameworks for plasma-derived products to ensure its safety and quality. Moreover, countries within Europe also focus on cost-effectiveness and efficiency, influencing choice in clinical trials for treatment therapies. Combined with its elderly population and high access to healthcare, Europe has been continuously developing clinical treatment standards for its colloidsal blood plasma products.

Germany Market Trends

Germany constitutes an essential European market owing to its sophisticated healthcare infrastructure, a broad hospital network and support from regulatory authorities on plasma therapies. The country holds a substantial number of beds in its hospitals across the region, providing a huge scope for critical care services. With its continually growing aging population, which is constituted of more than 22% of its total citizens aged over 65, demand is growing for plasma-derived treatments. Germany's support of plasma collection and fractionation processes also ensures a constant supply in the market. The clinical trials in Germany provide rational usage of albumin and other colloids to both the ICU and surgical departments. Growing medical facility-biopharmaceutical collaborations lead to better patient care and advanced treatment practices in the market.

Why Then Is The Middle East & Africa Region Growing?

The MEA region has witnessed significant growth attributed to escalating healthcare investments, rapid improvements in infrastructure and growing recognition of critical care therapies. The Gulf countries have a remarkable investment in the expansion of hospital networks and ICUs, leading to higher demand for plasma products. The World Health Organization states that over 70% of global deaths occur from non-communicable diseases, of which a substantial percentage is recorded in the MEA region, which in turn escalates demand for surgical & critical care procedures. Improvements in accessing healthcare facilities and a slow yet consistent growth in plasma collection systems are also fueling growth for colloids blood plasma in Africa. Partnerships with international organizations and governmental initiatives aimed at upgrading healthcare infrastructure are strengthening the use of colloidsal blood plasma in the region.

Top Players in the Market and Their Offerings:     

• CSL Behring

• Grifols S.A.

• Octapharma AG

• Kedrion Biopharma

• Shire (now part of Takeda Pharmaceutical Company Limited)

• Bio Products Laboratory Ltd.

• Sanquin Blood Supply Foundation

• China Biologic Products Holdings Inc.

• LFB Group

• Biotest AG

• Green Cross Corporation

• Baxter International Inc.

• Hualan Biological Engineering Inc.

• Shanghai RAAS Blood Products Co. Ltd.

• Emergent BioSolutions Inc.

• Kamada Ltd.

• ADMA Biologics Inc.

• Intas Pharmaceuticals Ltd.

• BPL Plasma

• PlasmaGen BioSciences Pvt. Ltd.

• Others

Key Developments

The market has been undergoing drastic changes as industry participants are focusing on developing products and portfolios to gain more capabilities.

• In Jan 2024 CSL Behring launched Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) pre-filled 10g syringe, which simplifies patient treatment by eradicating the need for vial preparation, reducing treatment time, and increasing convenience and support for compliance in home therapy for CIDP and PI patients.

• In Oct 2023, KTC Edibles launched their brand of Planet Palm - a new range of sustainably sourced and traceable palm oil products targeted towards UK food manufacturers. The products will have certifications for sustainability and aim to cater to the growing demand from food manufacturers for sustainable and traceable ingredients.

With the implementation of strategies such as the above, the companies have been able to enhance market presence, product portfolio, and technology and benefit from the growth opportunities in the changing market.  

The Colloids Blood Plasma Market is segmented as follows:

By Product Type

• Gelatin-Based Colloids

• Dextran-Based Colloids

• Hydroxyethyl Starch-Based Colloids

• Albumin-Based Colloids

• Others

By Application

• Trauma and Injury

• Surgery

• Burns

• Shock

• Others

By End Use

• Hospitals

• Ambulatory Surgical Centers

• Specialty Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America